Genetic variability at the human FMO1 locus: Significance of a basal promoter Yin Yang 1 element polymorphism (FMO1*6)

Journal of Pharmacology and Experimental Therapeutics

Volumn 306, Issue 3, 2003, Pages 1210-1218

  Hines, Ronald N ^a   Luo, Zhaohui ^a   Hopp, Kathleen A ^a   Cabacungan, Erwin T ^a   Koukouritaki, Sevasti B ^a   McCarver, D Gail ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; GENE PRODUCT; GUANINE; PROTEIN FMO1; THYMINE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CHINESE MEDICINE; CHROMOSOME 1Q; CONTROLLED STUDY; DNA POLYMORPHISM; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCUS; GENE STRUCTURE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTRON; KIDNEY; LIVER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; UNTRANSLATED REGION;

BASE SEQUENCE; DNA-BINDING PROTEINS; ERYTHROID-SPECIFIC DNA-BINDING FACTORS; HUMANS; MOLECULAR SEQUENCE DATA; OXYGENASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); TRANSCRIPTION FACTORS; VARIATION (GENETICS); YY1 TRANSCRIPTION FACTOR;

EID: 0041932063     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.053686     Document Type: Article

References (40)

1. Boucher PD, Ruch RJ, and Hines RN (1993) Specific nuclear protein binding to a negative regulatory element on the human CYP1A1 gene. J Biol Chem 268:17384-17391.
2. Cashman JR (2002) Flavin monooxygenases, in Enzyme Systems That Metabolize Drugs and Other Xenobioties (Ionnides C ed) pp 67-93, John Wiley & Sons, Inc., Indianapolis, IN.
3. Cashman JR, Celestial JR, Leach A, Newdoll J, and Park SB (1993a) Tertiary amines related to brompheniramine: preferred conformations for N-oxygenation by the hog liver flavin-containing monooxygenase. Pharm Res (NY) 10:1097-1105.
4. Cashman JR, Park SB, Yang Z-C, Washington CB, Gomez DY, Giacomini KM, and Brett CM (1993b) Chemical, enzymatic and human enantioselective S-oxygenation of cimetidine. Drug Metab Dispos 21:587-597.
5. Cashman JR, Zhang J, Leushner J, and Braun A (2001) Population distribution of human flavin-containing monooxygenase form 3: gene polymorphisms. Drug Metab Dispos 29:1629-1637.
6. Clement B, Lustig KL, and Ziegler DM (1993) Oxidation of desmethylpromethazine catalyzed by pig liver flavin-containing monooxygenase: number and nature of metabolites. Drug Metab Dispos 21:24-29.
7. Collins FS, Brooks LD, and Chakravarti A (1998) A DNA polymorphism discovery resource for research on human genetic variation. Genome Res 8:1229-1231.
8. den Dunnen JT and Antonarakis SE (2001) Nomenclature for the description of human sequence variations. Hum Genet 109:121-124.
9. Donohoe ME, Zhang X, McGinnis L, Biggers J, Li E, and Shi Y (1999) Targeted disruption of mouse yin yang 1 transcription factor results in peri-implantation lethality. Mol Cell Biol 19:7237-7244.
10. Furnes B, Feng J, Sommer S, and Schlenk D (2003) Identification of novel variants of the flavin-containing monooxygenase gene family in African Americans. Drug Metab Dispos 31:187-193.
11. Gasser R (1996) The flavin-containing monooxygenase system. Exp Toxicol Pathol 48:467-470.
12. Hines RN (2003) Phase I biotransformation reactions-flavin monooxygenase, in X-Pharm (Byland DB and Enna SJ eds) Elsevier Science, Amsterdam, in press.
13. Hines RN, Hopp KA, Franco J, Saeian K, and Begun FP (2002) Alternative processing of the human hepatic FMO6 gene renders transcripts incapable of encoding a functional flavin-containing monooxygenase. Mol Pharmacol 62:320-325.
14. Kim YM and Ziegler DM (2000) Size limits of thiocarbamides accepted as substrates by human flavin-containing monooxygenase. Drug Metab Dispos 28:1003-1006.
15. Koukouritaki SB, Simpson P, Yeung CK, Rettie AE, and Hines RN (2002) Human hepatic flavin-containing monooxygenase 1 (FMO1) and 3 (FMO3) developmental expression. Pediatric Res 51:236-243.
16. Krause RJ, Lash LH, and Elfarra AA (2002) Human kidney flavin-containing monooxygenases and their potential roles in cysteine S-conjugate metabolism and nephrotoxicity. J Pharmacol Exp Ther 304:185-191.
17. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391.
18. Lindblad-Toh K, Winchester E, Daly MJ, Wang DG, Hirschhorn JN, Laviolette J-P, Ardlie K, Reich DE, Robinson E, Sklar P, et al. (2000) Large-scale discovery and genotyping of single-nucleotide polymorphisms in the mouse. Nat Genet 24:381-386.
19. Lomri N, Gu Q, and Cashman JR (1992) Molecular cloning of the flavin-containing monooxygenase (form II) cDNA from adult human liver. Proc Natl Acad Sci USA 89:1685-1689.
20. Luo Z and Hines RN (1996) Identification of multiple flavin-containing monooxygenase form 1 (FMO1) gene promoters and observation of tissue-specific DNaseI hypersensitive sites. Arch Biochem Biophys 336:251-260.
21. Luo Z and Hines RN (1997) Further characterization of the major and minor rabbit FMO1 promoters and identification of both positive and negative distal regulatory elements. Arch Biochem Biophys 346:96-104.
22. Luo Z and Hines RN (2001) Regulation of flavin-containing monooxygenase 1 (FMO1) expression by yin yang 1 (YY1) and hepatic nuclear factors 1 (HNF1) and 4 (HNF4). Mol Pharmacol 60:1421-1430.
23. McCarver DG, Thomasson H, Martier SS, Sokol RJ, and Li T-K (1997) Alcohol dehydrogenase-2*3 allele protects against alcohol-related birth defects among African Americans. J Pharmacol Exp Ther 283:1095-1101.
24. Mendel DB, Hansen LP, Graves MK, Conley PB, and Crabtree GR (1991a) HNF-1 alpha and HNF-1 beta (vHNF-1) share dimerization and homeo domains, but not activation domains and form heterodimers in vitro. Genes Dev 5:1042-1056.
25. Mendel DB, Khavari PA, Conley PB, Graves MK, Hansen LP, Admon A, and Crabtree GR (1991b) Characterization of a cofactor that regulates dimerization of a mammalian homeodomain protein. Science (Wash DC) 254:1762-1767.
26. Mitchell SC and Smith RL (2001) Trimethylaminuria: the fish malodor syndrome. Drug Metab Dispos 29:517-521.
27. Mushiroda T, Douya R, Takahara E, and Nagata O (2000) The involvement of flavin-containing monooxygenase but not CYP3A4 in metabolism of itopride hydrochloride, a gastroprokinetic agent: comparison with cisapride and mosapride citrate. Drug Metab Dispos 28:1231-1237.
28. Nickerson DA, Tobe VO, and Taylor SL (1997) Polyphred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. Nucleic Acids Res 25:2745-2751.
29. Overby LH, Carver GC, and Philpot RM (1997) Quantitation and kinetic properties of hepatic microsomal and recombinant flavin-containing monooxygenases 3 and 5 from humans. Chem Biol Interact 106:29-45.
30. Park C-S, Kang J-H, Chung W-G, Yi H-G, Pie J-E, Park D-K, Hines RN, McCarver DG, and Cha Y-N (2002) Ethnic differences in allelic frequency for two flavin-containing monooxygenase 3 (FMO3) polymorphisms: linkage and effects on in vivo and in vitro FMO activities. Pharmacogenetics 12:77-80.
31. Reese MG, Eeckman FH, Kulp D, and Haussler D (1997) Improved splice site detection in Genie. J Comput Biol 4:311-323.
32. 1-muscarinic agonist xanomeline. Drug Metab Dispos 27:1099-1103.
33. Shi Y, Lee J-S, and Galvin KM (1997) Everything you wanted to know about yin yang 1. Biochim Biophys Acta 1332:F49-F66.
34. Thomas MJ and Seto E (1999) Unlocking the mechanisms of transcription factor YY1: are chromatin modifying enzymes the key? Gene 236:197-208.
35. Tronche F and Yaniv M (1992) HNF1, a homeoprotein member of the hepatic transcription regulatory network. Bioessays 14:579-587.
36. Whetstine JR, Yueh M-F, Hopp KA, McCarver DG, Williams DE, Park C-S, Kang Y-N, Cha Y-N, Dolphin CT, Shephard EA, et al. (2000) Ethnic differences in human flavin-containing monooxygenase 2 (FMO2) polymorphisms: detection of expressed protein in African-Americans. Toxicol Appl Pharmacol 168:216-224.
37. Wrighton SA, Brian WR, Sari M-A, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, and Vandenbranden M (1990) Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 38:207-213.
38. Yeung CK, Lang DH, Thummel KE, and Rettie AE (2000) Immunoquantitation of FMO1 in human liver, kidney and intestine. Drug Metab Dispos 28:1107-1111.
39. Zheng Y-M, Henne KR, Charmley P, Kim RB, McCarver DG, Cabacungan ET, Hines RN, and Rettie AE (2003) Genotyping and site-directed mutagenesis of a cytochrome P450 meander Pro-X-Arg motif critical to CYP4B1 catalysis. Toxicol Appl Pharmacol 186:119-126.
40. Ziegler DM (2002) An overview of the mechanism, substrate specificities and structure of FMOs. Drug Metab Rev 34:503-511.